الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 16 |  |  |
| | | from | 16 | | |
Abstract
Cirrhosis is considered the most advanced stage of chronic liver disease. Portal hypertension is one of the main consequences of cirrhosis. It can result in many complications, including splenomegaly, esophagogastric varices, and ascites, as well as spontaneous bacterial peritonitis and hepatorenal syndrome. Cirrhotic patients are recommended to undergo screening endoscopy for the presence of EV. Nonselective beta-blockers (NSBBs) (i.e. propranolol, nadolol, and timolol) reduce the portal pressure by decreasing portal and collateral blood flow. This effect is achieved via the blockade of both the beta-1- adrenoreceptors, causing a reduction in cardiac output and the beta-2- adrenoreceptors in the splanchnic vasculature, causing an unopposed α- adrenergic splanchnic arterial vasoconstriction. Several randomized trials and cost-effectiveness analyses have demonstrated that non selective b-blockers are the first choice medications for primary prophylaxis against variceal bleeding in patients with varices. Limited information is available regarding the role of NSBBs in other portal hypertension complications other than varices and variceal bleeding. The aim of this study was to evaluate the effects of propranolol, as one of non-selective beta blockers, on non-variceal complications of portal hypertension as ascites, hypersplenism, incidence of SBP and HRS. This study was conducted on one hundred patients with liver cirrhosis and evidence of portal hypertension attending the outpatient clinics of the Hepatology Department, National Liver Institute, Menoufyia University. All patients were subjected to full history taking, thorough clinical examination, and investigations including complete blood count, liver tests (AST, ALT, serum albumin, total & direct bilirubin), prothrombin time and INR, serum creatinine and urea, abdominal ultrasonography and Doppler studies, and upper endoscopy. This study concluded that propranolol could be safe and effective in the management of non-variceal complications in cirrhotic patients especially thrombocytopenia.